Trending Topic

3D Rendered Medical Illustration of The Lungs.
12 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked
Asrar A Alahmadi, Logan Roof, Claire Verschraegen

Highlights Immunotherapy, especially combinatory immunotherapy, has shown promise with prolonged survival for patients with advanced mesothelioma in the first-line setting (see the sections on ‘Systemic treatment and immunotherapy debut’ and ‘Randomized immunotherapy trials of mesothelioma’). Histology-based therapy is important to consider, with non-epithelioid subtypes responding better to immunotherapy than to chemotherapy (see the section on […]

Sebastian Schmid, ESMO 2022: RACE-IT – RAdiation therapy before radical CystEctomy combined with ImmunoTherapy in advanced bladder cancer

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Sep 15th 2022

Patients with locally advanced bladder cancer have a poor prognosis despite surgical therapy. Prof. Sebastian Schmid (Technical University of Munich, Munich, Germany) joins touchONCOLOGY to discuss the unmet needs in the treatment of locally advanced bladder cancer, and also discusses the feasibility, safety and efficacy of neoadjuvant radio-immunotherapy following radical cystectomy in patients with locally advanced, muscle invasive bladder cancer.

The abstract entitled ‘RACE IT: A prospective, single arm, multicenter, phase II-trial to assess safety and efficacy of preoperative RAdiation therapy before radical CystEctomy combined with ImmunoTherapy in locally advanced urothelial carcinoma of the bladder (AB 65/18) – first results‘ Abstract LBA75, was presented at European Society for Medical Oncology (ESMO) 2022.

Questions:

  1. What are the unmet needs in the treatment of locally advanced bladder cancer, and what was the rationale for the investigation of preoperative radiation therapy before radical cystectomy combined with immunotherapy in this treatment setting? (0:13)
  2. What were the aims, design, and study endpoints, and how well were they achieved? (2:30)
  3. What will be the next steps in the clinical development of this therapeutic approach? (4:21)

Disclosures: Sebastian Schmid receives grant/research support from Bristol-Myers Squibb.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Katey Gabrysch.

Filmed in coverage of ESMO 2022

Access more bladder cancer content here

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup